Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-09-07-Speech-3-126"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2005-09-07"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"en"^^xsd:language2
lpv:document identification number	"en.20050907.15.3-126"2
lpv:hasSubsequent	lp_eu:2005-09-07-Speech-3-1272
lpv:speaker	lp:David Martin2
lpv:spoken text	". I warmly welcome this proposal. A decade or more after the USA, the EU is at last set to adopt legislation requiring the testing of pharmaceutical products for children as part of their approval process. These new rules should ensure that more drugs are developed for children and that they are administered in safe and effective dosages. In return for pharmaceutical companies carrying out mandatory clinical trials for drugs intended for use in children they will be given financial compensation. The financial compensation proposed by the Commission involves granting companies an extra six months Supplementary Protection Certificate, that is, a form of extended patent. This must be monitored to ensure that it does not lead to excessive profits."@en1
lpv:spokenAs	substitute; Delegation to the EU-Bulgaria Joint Parliamentary Committee (2004-09-15--2006-12-31)3 member; PES (2004-07-20--2009-07-13)3 member; PETI (2004-10-13--2007-01-14)3 unknown; Labour Party (2004-07-20--2009-07-13)3 substitute; AGRI (2004-07-21--2006-03-15)3 member; Delegation for relations with Australia and New Zealand (2004-09-15--2007-03-13)3 member; INTA (2004-07-21--2007-01-14)3
lpv:unclassifiedMetadata	"David Martin (PSE ),"1 "in writing"1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph